Nature Reviews Cardiology, Published online: 28 May 2025; doi:10.1038/s41569-025-01176-5Reply to ‘Neuroendocrine regulatory effects of sex hormones on salt sensitivity of blood pressure’

Nature Reviews Cardiology, Published online: 20 May 2025; doi:10.1038/s41569-025-01170-xConference presentation skills are a crucial, yet often overlooked, element in the dissemination of cardiovascular research. In an era of information overload and digital communication, the ability to clearly and engagingly present scientific data is essential, to ensure that the findings are understood, shared and implemented into clinical practice.

Nature Reviews Cardiology, Published online: 12 May 2025; doi:10.1038/s41569-025-01169-4A new study published in Nature reveals the role of the interaction between the circadian transcription factor BMAL1 and hypoxia-inducible factor 2α in circadian-dependent cardioprotection after ischaemia–reperfusion injury, and highlights the potential of chronotherapeutic approaches for ischaemic heart disease.

Nature Reviews Clinical Oncology, Published online: 29 May 2025; doi:10.1038/s41571-025-01034-wIn pivotal trials testing daratumumab in patients with transplant-ineligible newly diagnosed multiple myeloma, inadequate crossover provisions have not only compromised the interpretation of survival data but also left fundamental questions about optimal treatment sequencing unanswered. Herein, we address the ethical implications of trial designs that fail to guarantee access to effective post-progression therapy for patients in the control arm, particularly in studies across regions in which standard-of-care treatment varies dramatically.

Nature Reviews Clinical Oncology, Published online: 16 May 2025; doi:10.1038/s41571-025-01021-1Despite advances in drug development, some patients with non-small-cell lung cancer (NSCLC) have suboptimal responses to treatment. The authors of this Review provide an overview of the complexity of the tumour microenvironment in NSCLC, including the influence of patient-related factors, such as ageing, sex and health disparities, on the cancer–TME crosstalk, and discuss how various therapeutic strategies interact with and are influenced by the TME in NSCLC.

Nature Reviews Clinical Oncology, Published online: 14 May 2025; doi:10.1038/s41571-025-01020-2Patients with resectable glioblastoma undergo upfront surgery followed by adjuvant radiotherapy plus chemotherapy. This approach implies a period of approximately 4–6 weeks between surgery and the start of adjuvant therapy in which the patient receives no active treatment. In this Perspective, the authors describe the potential of local therapies targeting the tumour resection margin that can be administered during this time window, including biological feasibility, the potential role of nanomedicines and various technical and regulatory challenges that will need to be addressed before clinical implementation becomes feasible.

Nature Reviews Clinical Oncology, Published online: 13 May 2025; doi:10.1038/s41571-025-01025-xAnal squamous cell carcinoma (ASCC) is a rare malignancy, albeit with an increasing prevalence in most economically developed countries. Despite considerable advances in our understanding of the biology of ASCC, chemoradiotherapy (CRT) remains the standard-of-care therapy for most patients, albeit with promising data emerging on the role of CRT plus immune-checkpoint inhibitors in the metastatic setting. In this Review, the authors describe the biology of ASCC and relate this to the various attempts to improve outcomes via the development of more effective systemic therapies and/or combinations.